GlassScriptPhysician profile
Matthew P Goetz
NPI 1255310611
$136,263.34
in general payments reported to CMS, 2019-2025
15 companies · $35K in 2025
The $35K reported for 2025 was more than what 93% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $8,965 · 2021: $6,512 · 2022: $8,245 · 2023: $30K · 2024: $27K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $73K · Travel and Lodging: $17K · Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $72,727.13 |
| Travel and Lodging | $17,308.60 |
| Food and Beverage | $1,187.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $55,071.37 | 2019-2025 | Verzenio |
| Eli Lilly and Company | $39,959.10 | 2019-2025 | Verzenio |
| Novartis Pharmaceuticals Corporation | $7,907.69 | 2020-2025 | Kisqali |
| Puma Biotechnology, INC. | $5,221.00 | 2022-2025 | |
| Genentech, INC. | $4,620.00 | 2025 | Venclexta, Perjeta |
| Astrazeneca Pharmaceuticals LP | $4,425.01 | 2022-2025 | |
| Genentech USA, INC. | $3,800.00 | 2024 | Itovebi |
| Tersera Therapeutics LLC | $3,420.88 | 2023 | Zoladex |
| Blueprint Medicines Corporation | $3,248.00 | 2021-2022 | |
| Eagle Pharmaceuticals, INC. | $3,000.00 | 2020 | |
| Seagen INC. | $2,323.00 | 2022 | |
| Genzyme Corporation | $1,739.81 | 2021 | |
| Astrazeneca Uk Limited | $1,515.56 | 2022-2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Goetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.